证券代码：002653 证券简称：海思科 公告编号：2025-128

Group 1 - The core announcement is that the company's drugs,环泊酚注射液 and 安瑞克芬注射液, have been included in the National Medical Insurance Catalog (2025 version) [1][2] - 环泊酚注射液 is a new intravenous anesthetic developed by the company, with its active ingredient being the (R)-configured isomer, which acts as a GABAA receptor agonist [1] - 安瑞克芬注射液 is a high-selectivity peripheral kappa opioid receptor agonist and is the first non-narcotic prescription opioid analgesic approved for pain relief without being classified as a controlled substance [2] Group 2 - The inclusion of these drugs in the National Medical Insurance Catalog is expected to facilitate market promotion and future sales of innovative products [2] - The National Medical Insurance Catalog (2025 version) will officially take effect on January 1, 2026, and is not expected to have a significant short-term impact on the company's operating performance [2]